Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

About the trial

Sponsor

AbbVie

Tested

ABBV-706 (drug), Cisplatin (drug), Budigalimab (drug), Carboplatin (drug)

Dates

Started 2022-12-05; completion 2027-11

Results posted

Not yet

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at d…

From ClinicalTrials.gov, last updated 2026-05-07. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $4.7M in research payments for this study in 2025 (2,170 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.